Track 05 of 14
Cardiometabolic Medicine
GLP-1 agonists, obesity, diabetes-CV-kidney axis and CKM syndrome.
The cardiometabolic field has been redefined by incretin-based therapy: SELECT (semaglutide), SURMOUNT-MMO (tirzepatide), STEP-HFpEF, and FLOW have positioned GLP-1 and dual GIP/GLP-1 agonists as cardiovascular and kidney drugs. The track formalizes the AHA Cardiovascular-Kidney-Metabolic (CKM) staging framework, examines retatrutide and orforglipron in upcoming readouts, and integrates finerenone across the diabetic-CKD-HF spectrum. Sessions address obesity as a primary CV risk factor, MASLD/MASH as an emerging cardiometabolic node, and the operational shift to multi-disciplinary CKM clinics.
Focus areas
- GLP-1 and dual agonists: SELECT, SURMOUNT-MMO, STEP-HFpEF, FLOW
- Pipeline: retatrutide, orforglipron, survodutide
- CKM syndrome: AHA staging and clinic operational models
- Finerenone across diabetic CKD and HFpEF (FINEARTS-HF)
- MASLD/MASH and cardiovascular risk
- Obesity as a primary cardiovascular risk factor
- Type 2 diabetes prevention and pre-diabetes management